Cardiac devices and advanced heart failure: Are we selecting the wrong patients?

Patients with advanced heart failure may be receiving implantable cardiac devices that do not help them because they are too ill to benefit from the treatment, a Saint Louis University study found.

"Implantable cardiac devices were not intended for, or studied as 'rescue therapy' for very ill hospitalized patients with heart failure," said Paul Hauptman, M.D., professor of internal medicine at Saint Louis University School of Medicine and senior study author of the study.

"Overuse of these devices is a disservice to patients, because it puts them through unnecessary procedures and creates unrealistic expectations for the device."

The researchers looked at in-hospital mortality rates of patients who received a cardiac resynchronization device (biventricular pacemaker) to coordinate the contractions of the heart, implantable cardioverter defibrillator to prevent sudden cardiac death or both, to identify which patients are poor candidates for the procedure.

The findings will help doctors decide which patients should receive the devices, and may help to make heart failure care more cost-effective.

"This is a first, but very important, step in better defining who should get these devices," Hauptman said. "This study will have implications for cost-effectiveness, quality and appropriateness of care, and the experience patients and their families have with the disease."

Implantable cardiac devices have transformed the care of patients with heart failure by adding a safe, non-pharmacologic treatment option, Hauptman says. However, clinical trials designed to test the safety and effectiveness of the devices did not, in general, enroll patients with heart failure who experience prolonged hospitalizations prior to device implantation or who require advanced, largely palliative therapies such as inotropic therapy at the time of implantation, both markers of poor prognosis.

"Decision-making for patients who have very advanced symptomatic heart failure is complex but the guidelines for patient selection emphasize that device implantation should be limited to those who are expected to have, at the very least, a one year life expectancy" Hauptman said.

According to the study, the average healthcare cost for patients who received one or both of the devices was $43,735. The costs were nearly double that amount if the patient died. The cost-effectiveness of these devices is determined by comparing the cost of the procedure to the number of quality years added to the patient's life.

"Although a rigorous, cost-effective study is still needed, our data suggest these procedures are being performed on patients who are unlikely to derive benefit," Hauptman said.

Using a national database from 2004-2005 of nearly 28,000 patients from 240 hospitals, the researchers identified two red flags that were associated with higher risk of in-hospital mortality. According to the researchers, these red flags need to be considered when deciding whether or not a patient is a good candidate for the devices.

Patients who received inotropic therapy before or after the procedure were at the highest risk for in-hospital mortality. Inotropic drugs alleviate the symptoms of advanced heart failure by making the heart pump more vigorously. However, because the drugs potentially increase the risk of death, they are used as for symptom control and as a palliative measure for the most severely sick patients.

"In our analysis, 24.1 percent of patients who receive inotropic drugs, whether or not they received a cardiac device,, die before leaving the hospital," Hauptman said. "Clearly, patients who need, or will likely need, inotropic therapy are very ill and unlikely to receive long-term benefit from these devices.

"Future guidelines regarding the appropriate use of these devices should incorporate the ongoing or anticipated need for inotropic therapy."

Another red flag in their research was the timing of the procedure. Most patients received the devices on the first day of their hospitalization, indicating that it was an elective procedure. Patients, who received the devices after an extended hospitalization, indicating the procedure was likely non-elective, were at risk for in-hospital mortality.

Source: Saint Louis University

Related stories:

The beat goes on: Artificial heart technology holds promise for alternatives
Patients on the waiting list for a heart transplant soon may have more options thanks to a new device being developed by the Texas Heart Institute in collaboration with two University of Houston professors.
Are we spending too much on health?
In this poor economic climate and period of lower growth is it time to consider limiting spending on healthcare budgets? Two experts debate the issue on bmj.com today.
Study shows radiation device may customize therapy, enable some to avoid more lengthy treatment
A study of the first approximately 100 patients who have received partial breast irradiation with a small, whisk-like, expandable device inserted inside the breast has shown that after one year, the device is effective at sparing nearby healthy tissue from the effects of radiation. The device, called SAVI™, is aimed at providing customized radiation therapy while minimizing exposure to healthy tissue around the breast after a woman has received a lumpectomy for early stage cancer.
Optical sensors make MRI scans safer
(PhysOrg.com) -- Magnetic resonance scans will be safer for children and other patients needing anaesthesia, thanks to new kinds of optical sensors developed by a team of European researchers.
Prosthetic vein valve designed to direct blood flow shows promising pre-clinical results
Engineers at the Georgia Institute of Technology have developed a prosthetic vein valve to help improve the lives of those suffering from a condition known as chronic venous insufficiency. The condition, which affects more than seven million people in the United States alone, occurs when valves in a person's veins can no longer ensure a one-way flow of blood back to the heart.
Deep brain stimulation offers hope to people with treatment-resistant illnesses
Every day during a four-year deep depression, Sean Miller thought of ending his life. Nothing relieved the emotional darkness - not therapy, not medication, not loving attention from family and friends.
Bacteria's sticky glue is clue to vaccine says scientist
Sticky glue secreted by the bacterium Staphylococcus aureus could be the clue scientists have been searching for to make an effective vaccine against MRSA, medical researchers heard today at the Society for General Microbiology's Autumn meeting being held this week at Trinity College, Dublin.
Cardiac ultrasound imaging goes to handheld
Non-invasive imaging has revolutionized the diagnosis of the most common cardiac diseases such as valve problems and coronary heart disease. In addition, imaging techniques are developing rapidly and we anticipate that non-invasive imaging will gain further importance in the treatment of cardiac patients.

News discussion:

Medicine & Health news